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Abstract A prospective, open trial was conducted to
evaluate the nutritional adequacy of a semi-elemental diet
in 47 children with functional gastro-intestinal disorders.
Nutritional adequacy was assessed based on growth relative
to Euro-growth standards for body mass index (BMI)-for-
age z-scores and evaluations of blood parameters. Twenty-
ﬁve patients completed the study. In total, 533 l of
‘‘New-Alfare’’ was consumed during 775 trial-days. The
mean intake per infant was 85.8 ± 26.8 kcal/kg/day or
122.5 ± 38.3 ml/kg/day. Weight and length evolution
during the 4 weeks trial were within normal range. The
mean BMI-for-age z-score (P\0.05) and albumin con-
centration (P\0.01) increased signiﬁcantly after 4 weeks.
Plasma threonine concentration decreased signiﬁcantly
(P = 0.01) and the tryptophan concentration increased
(P = 0.06). No adverse events related to the study formula
were reported. These results show that ‘‘New Alfare ´’’ is safe
and nutritionally adequate for pediatric patients with gastro-
intestinal disease.
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Abbreviations
AE Adverse events
BMI Body mass index
CMPA Cow’s milk protein allergy
CRP C-reactive protein
GI Gastro-intestinal
ITT Intent-to-treat
PP Per protocol
RBP Retinol binding protein
Introduction
Infants with enteropathy who cannot be breast-fed, are best
treated by replacing milk from their diet with alternative
formulas based on hydrolyzed proteins or on amino acids.
Hydrolyzed formulas have been shown to provide adequate
nutrition in asymptomatic, unselected, healthy infants
(Vandenplas et al. 1993; Exl et al. 2000). In one of these
studies, hydrolyzed formula was shown to promote normal
growth of healthy infants during at least the ﬁrst 3 months
of life even though the mean caloric intake was lower than
that of infants fed on non-hydrolyzed formula (Vandenplas
et al. 1993). Concentrations of zinc, urea, and iron binding
capacity were also higher in infants fed on the hydrolyzed
formula (but within normal range), and all other blood
nutritional parameters were similar in the two groups
(Vandenplas et al. 1993).
On the other hand, in infants with enteropathy of hetero-
geneousetiology,suchaspost-enteritissyndromeandcow’s
milk protein allergy (CMPA), the nutritional situation is
different. For instance, it has been shown that children with
CMPA ingest signiﬁcantly smaller volumes of formula, and
thereforealowerintakeofcalories,proteinandfatcompared
to normal children (Tiainen et al. 1995). Consequently,
allergic children on elimination diets who are not fed
hydrolyzed formulas are signiﬁcantly smaller than non-
allergic children (Tiainen et al. 1995; Christie et al. 2002).
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infants consumed less than 67% of the dietary reference for
calcium, vitamin D and vitamin E, compared to healthy
infants (Christie et al. 2002). Because children with GI dis-
eases on an elimination diet are at an increased risk for
growth retardation, their nutritional intake has to be closely
monitored and formulas with sufﬁcient supplementation of
nutrients with improved absorbability need to be provided.
In the current study, we evaluated the nutritional ade-
quacy and short-term safety of a formula for infants who
require enteral feeding. This formula is based on an
improved protein hydrolysis technique that generates an
amino acid proﬁle that better resembles that of breast milk
(lower concentration of threonine) compared to the previ-
ous formula (Alfare ´). It also contains nucleotides, which
are thought to have beneﬁcial effects on the immune and
GI systems of infants (Yau et al. 2003; Carver 1999;
Brunser et al. 1994).
Subjects and methods
Study design and population
This was a prospective, open, 4-week, mono-center study
carriedoutintheDepartmentofPediatricsattheUniversitair
Ziekenhuis Brussel (Brussels, Belgium). Inclusion criteria
weregestationalageofC26 weeks,weighingC1,500 g,and
being B36 months old at the time of the study. Infants and
children that were hospitalized because of a variety of
symptomsofGIdisease andrequireddiagnostic workupand
nutritional treatment with a semi-elemental formula for at
least 1 month were eligible for inclusion. Patients who were
less than 1-year old were fed solely with the study formula
for 4 weeks, and for those older than 1 year the study for-
mula constituted C75% of the total caloric intake. Patients
who were expected to be fed exclusively through parenteral
route for longer than a month were not eligible.
Weight, length, and blood parameters were measured at
the beginning (day 0) and end (day 28 ± 3) of the study.
Additional weight measurements were taken at weekly
intervals. Acceptability and tolerance (volume of formula
intake, GI symptoms, and stool characteristics) were
recorded daily by the parents.
This study was approved by the Ethical Committee of
Vrije University (VUB, Brussels, Belgium) and conformed
to the Helsinki Declaration. Parents of all patients gave
their written consent.
Product
The study formula, New Alfare ´ (Nestle ´, Switzerland), was
a nutritionally complete, semi-elemental formula based on
extensively hydrolyzed acid whey. It consisted of small
peptides (80%) and amino acids (20%), fat, carbohydrates,
and nucleotides (Tables 1, 2).
Outcome measures
The primary outcome was growth relative to Euro-growth
references (van’t Hof and Haschke 2000). Weight was
measured to the nearest 0.1 kg on electronic scales and
length was measured to the nearest 5 mm using a stan-
dardized length board. BMI-for-age z-scores were calcu-
lated based on the Euro-growth references. The secondary
outcomes were tolerance and nutritional adequacy. Toler-
ance was evaluated based on: intake of the study formula
(volume and calories/kg weight/day); stool characteristics,
based on frequency in 24 h, consistency (liquid, soft,
formed, and hard), color (black, brown, green, and yellow),
and presence or absence of blood in stools; and GI symp-
toms (occurrence of ﬂatulence and cramps and the fre-
quency of spitting up or vomiting). Nutritional adequacy
was evaluated based on measurements of blood concen-
trations of albumin, amino acids, retinol binding protein
(RBP), and erythrocyte lipid proﬁles. Concentrations of
sodium, chloride, potassium, bicarbonate, calcium, urea,
C-reactive protein (CRP), alkaline phosphatase, urea
nitrogen, triglycerides were also determined using standard
analytical procedures. All blood parameters were measured
at the beginning and end of the study.
Adverse events (AE)
AE were deﬁned as illnesses and signs or symptoms of
illnesses that occurred or worsened during the course of the
study, or any abnormal laboratory ﬁndings. All AE was
Table 1 Nutritional content of the study formula compared to the
previous formulation and to human milk
New Alfare ´ Alfare ´ Human milk
Protein (g/100 kcal) 3.0 3.4 1.85
Amino acids (mg/100 kcal)
Threonine 120 278 77
Tryptophan 79 64 32
Nucleotides (mg/100 kcal) 8 – 4.5–4.9
Fat (g/100 kcal) 5.1 5.0 5.8
Total saturated (%) 52.2 65.2 43
Total monounsaturated (%) 29.5 20.2 41
Total polyunsaturated (%) 18.1 14.6 16
MCT
a (% ) 39.6 48 2.0
Carbohydrate (g/100 kcal) 10.9 10.8 10.8
a MCT medium chain triglyceride
Values for breast milk are based on human milk for full-term infants
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123evaluated and assessed for seriousness and relation to the
study formula by the investigator.
Statistical analysis
To obtain an accuracy of 0.2 z-points in the improvement
of BMI with 95% conﬁdence, 25 patients were required to
complete the study. Assuming a 20% dropout, 32 patients
had to be enrolled. For patients who had a gestational age of
\37 weeks, their BMI z-scores were calculated based on
their corrected age (subtracting the difference between
their gestational age and 37 from their current age). Both
primary and secondary outcomes were analyzed in the per
protocol (PP) population. AE was analyzed in the intent-to-
treat (ITT) population.
Mean plasma amino acid and fatty acid concentrations
on days 0 and 28 were compared by paired t test.
Results
Study population
Forty-seven patients with symptoms of functional GI dis-
eases, suggesting enteropathy, malabsorption, or CMPA
were enrolled in the study (ITT population). Nineteen
patients dropped out from the study either because they
refused to drink the study formula or because the parents
chose not to continue in the study, and two infants were
withdrawn by the investigator due to persistent vomiting.
One infant was dropped from the analysis because of lack
of data on length, blood analysis or tolerance. Thus, there
were 25 infants (11 boys and 14 girls) in the PP population
(Table 3). They had been admitted to hospital for post-
enteritis syndrome, including necrotizing enterocolitis
(n = 2), gastroenteritis including rota virus infection
(n = 8), food allergies including suspected and conﬁrmed
CMPA (n = 8) and other GI problems (e.g., failure to
thrive, chronic diarrhea, and intestinal colic, n = 7).
Outcomes
Mean weight-for-age z-score did not change (P[0.05)
whereas mean length-for-age z-score showed a signiﬁcant
decreaseattheendofthestudy(P\0.005).ThemeanBMI-
for-age z-score showed a signiﬁcant increase after 4 weeks
of feeding with the study formula (mean change = 0.54
[95% CI:?0.09 to ?0.99], P = 0.02, Fig. 1). One of the
premature infants showed the largest increase in BMI-for-
age z-score, but even when its data were removed from
analysis there was still a signiﬁcant increase in mean the
BMI-for-age z-score (data not shown).
The patients in the PP population consumed an average
of 122.5 ± 38.3 ml/kg/day corresponding to 85.8 ±
26.8 kcal/kg/day (range: 35–137 kcal/kg/day). They had an
average stool frequency of 2.1 ± 1.2/day, with soft and
formed stools occurring more frequently (54%) than liquid
stools (15%). No hard stools were reported. Brown and
yellow stools occurred at about the same frequency as
green stools (33 vs. 32%) and blood was reported once in
the stools of three patients. During the feeding period with
the study formula, there was a record of at least one inci-
dence of ﬂatulence in 16 infants (64%), cramps in 19
infants (76%), spitting up in 20 infants (50%), and vom-
iting in 17 infants (68%).
Compared to the beginning of the study, there was a
signiﬁcant increase in albumin concentration (from
3.45 ± 0.55 to 3.83 ± 0.58 g/dl, P\0.001) at the end of
the study. All other blood parameters, excluding amino
acid concentrations, remained within the normal range, and
apart from sodium concentration (which decreased
slightly) did not show any signiﬁcant change during the
study.
The plasma concentrations of threonine and four non-
essential amino acids (aspartate, glutamine, glycine, and
serine) decreased signiﬁcantly (P B 0.01, Fig. 2) at the end
of the study. On the other hand, the concentration of
Table 2 Peptide proﬁle (% of total peptide) of New Alfare ´ and
Alfare ´
Number of Amino Acids
(molecular weight in Da)
% of total
peptides
New Alfare ´
1–2 (\240) 25
3–5 (240–600) 43
5–10 (600–1,200) 26
[20 ([2,400) 0.3
Alfare ´
1( \200) 22
2–3 (200–500) 40
4–9 (500–1,500) 26
[20 ([2,400) 1
Table 3 Baseline characteristics of the PP population at enrolment
n Mean (SD) Median Range
Gestational age (weeks) 25 38.6 (3.0) 39.0 28.0–41.0
Age (weeks)
a 25 23 (20) 19 3–87
Weight (g) 25 3,139 (733) 3,280 1,090–3,990
Length (cm) 24 49.2 49.6 39.0–52.0
BMI (kg/m
2) 25 13.17 13.50 7.17–15.83
a Age at the beginning of formula administration (day 0)
Optimized feeding in cow milk enteropathy 911
123tryptophan tended to increase (from 49.0 to 58.9 lmol/l),
with the ratio of tryptophan relative to the other neutral
amino acids (isoleucine, leucine, valine, phenylalanine, and
tyrosine) higher at the end of the study (P = 0.07). There
were no signiﬁcant differences in the concentrations of
short- and medium-chain fatty acids between the beginning
and end of the study (data not shown). However, there was
a signiﬁcant increase in the concentrations of some long-
chain fatty acids including di-homogammalinolenic acid
(C20:2n-6), arachidonic acid (C22:4n-6), and eicosapen-
tanoic acid (C20:5n-3). There was a signiﬁcant decrease in
the concentrations of palmitoleic acid (C16:1n7c), behenic
acid (C22:0), and arachidic acid (C20:0) (Table 4).
Fifty-four adverse events were reported in 26 patients.
Most of these were GI disorders (Table 5). The rest
included infections, respiratory disorders, and medical
procedures such as vaccination and mineral or vitamin
supplementation. None of the AE was assessed to be
related to the study formula. No serious adverse events
occurred during the trial.
Discussion
Development of infant formula is geared towards attaining
a similar nutritional proﬁle as human milk. Extensively
hydrolyzed, whey-predominant formulas developed for
infants with food allergies have been shown to promote
growth of healthy infants similar to those who are breast-
fed infants (Raiha et al. 2002; Vandenplas et al. 1993).
Nevertheless, the nutritional adequacy of these formulas in
sick children cannot be taken for granted. Thus, in this
study, we evaluated whether New Alfare ´ is safe and pro-
vides sufﬁcient nutrients in sick infants and children.
The subjects in this study were hospitalized infants and
children, all of whom had GI problems severe enough to
require enteral feeding. Their BMI-for-age z-scores relative
to Euro-growth standards increased after 4 weeks of
feeding with the new study formula (P\0.05), suggesting
the patients were catching up to the BMI of healthy infants.
47 infants enrolled 
Data from 22 infants 
excluded from analysis: 
- 19 dropouts due to 
infants refusal to drink 
formula or parents’ 
decision
- 2 dropouts due to 
persistent vomiting 
-1 infant with 
insufficient data 
Data from 25 infants 
available for PP analysis 
Fig. 1 Flow chart of patients in
the study
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Fig. 2 Mean ± SD plasma amino acid concentration of patients in
the PP population. (a) Concentration of essential amino acids and (b)
concentration of non-essential amino acids. * indicates t test P B 0.01
Table 4 Mean (standard deviation) percent of fatty acid acids with
signiﬁcant change after 4 weeks on study formula
Fatty acid Before After P-value
a
C20:3n6 2.13 (0.74) 2.57 (0.74) \0.001
C20:5n3 0.44 (0.16) 0.54 (0.15) \0.001
C22:4n6 4.26 (0.48) 4.44 (0.47) 0.04
C16:1n7c 0.32 (0.16) 0.26 (0.11) 0.02
C20:0 0.37 (0.12) 0.28 (0.09) \0.01
C22:0 1.08 (0.44) 0.84 (0.41) 0.02
a Comparisons made by paired t test
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123However, we are cautious in interpreting this observation;
even though mean weight-for-age z-score was the same at
the beginning and end of the study (P[0.05), suggesting
that the patients grew at a similar rate compared to the
Euro-growth standards, there was a signiﬁcant decrease in
the mean length-for-age z-score at the end of the study
(P\0.005). Despite the statistical signiﬁcance of the
decrease in the mean length-for-age z-score, we do not
think that this change is of clinical importance since the
study period was probably too short to see any meaningful
change in length. Furthermore, length measurements for
this population are prone to high error rates and small
changes cannot be accurately determined. Caution is also
warranted in interpreting the lower BMI of infants in this
study compared to Euro-growth references since the sub-
jects were sick and some growth problems were to be
expected. Thus, similar studies with longer duration will be
necessary to conﬁrm these results.
Whey- and total cow milk-based formulas contain
much higher concentrations of amino acids and conse-
quently, formula-fed infants tend to have higher plasma
amino acid concentrations (Raiha 1989). A correlation
between the amino acid concentrations in formulas and
the plasma of infants fed on these formulas has been
suggested previously (Priolisi et al. 1992; Rigo et al.
1989). Threonine, in particular, is present at signiﬁcantly
higher concentrations (two to three times higher) in
infants fed whey-based formulas compared to infants fed
human milk (Darling et al. 1999; Janas et al. 1985; Rigo
et al. 1994a). This has called the safety of these formulas
into question and recommendations to reduce threonine in
infant formulas have been made (Picaud et al. 2001; Rigo
et al. 1994b).
Accordingly, New Alfare ´ has a reduced threonine con-
centration compared to the previous formulation (Alfare ´).
After 4 weeks of feeding with New Alfare ´, the plasma
concentration of ﬁve amino acids, including threonine,
showed a signiﬁcant decrease but they remained within the
normal range. The mean plasma threonine concentration at
the end of the study (162.3 ± 53.6 lmol/l) was similar to
concentrations observed in breast-fed infants (Janas et al.
1985; Jarvenpaa et al. 1982), suggesting that the threonine
level in patients may have been effectively modulated by
New Alfare ´.
Similarly, the concentration of tryptophan, which was
higher in New Alfare ´ compared to Alfare ´, tended to
increase in the patients at the end of the study. Unlike
threonine, plasma concentration of tryptophan is gener-
ally lower in formula-fed infants compared with breast-
fed infants (Fazzolari-Nesci et al. 1992; Janas et al.
1987; Lonnerdal and Chen 1990) and has raised concerns
that this may cause metabolic or behavioral effects.
Although no clear evidence is available from clinical
trials, as a precursor of serotonin, tryptophan has been
hypothesized to affect the sleeping behavior of infants.
The relative increase in plasma concentration of trypto-
phan compared to the other neutral amino acids suggests
that the proportion of tryptophan delivered to the brain is
likely to increase. Finally, mean albumin concentration,
which was below the normal range at the beginning of
the study, increased signiﬁcantly at the end of the study
to within normal concentrations, indicating an improve-
ment in the nutritional status of patients.
This study suggests that the new hydrolysis technique
used in the preparation of New Alfare ´ appears to
improve the nutritional quality of the formula by sup-
plying less threonine and more tryptophan than stan-
dard hydrolyzed formulas. We demonstrated that ‘‘New
Alfare ´’’ has good short-term acceptability, tolerance,
nutritional adequacy, and safety in infants and children
who require semi-elemental diet for a variety of GI
problems. Nevertheless, the effect of the formula on the
growth of infants with GI diseases should be conﬁrmed
in long-term studies.
Table 5 Adverse events reported in the study (ITT population)
Adverse event preferred term Number of
events
Number of
patients
with the event
Gastrooesophageal reﬂux disease 13 10
Oesophagitis 7 7
Vitamin supplementation 4 4
Prophylaxis 3 3
Spesis 3 2
Enterocolitis infectious 2 1
Gastric disorder 2 2
Pancreatic insufﬁciency 2 2
Constipation 2 2
Bronchiolitis 2 1
Diarrhoea 1 1
Allergic colitis 1 1
Otitis media acute 1 1
Pneumonia bacterial 1 1
Increased viscosity of bronchial
secretion
11
Pneumonia 1 1
Anaemia neonatal 1 1
Neonatal apnoeic attack 1 1
Convulsion 1 1
Iron deﬁciencies 1 1
Pruritus ani 1 1
Laryngeal oedema 1 1
Eczema 1 1
Reﬂux gastritis 1 1
Optimized feeding in cow milk enteropathy 913
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